These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24670510)

  • 1. [The polypill as cardiovascular prophylactic: clinical trials].
    Sandli OK; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2014 Mar; 134(6):620-3. PubMed ID: 24670510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
    Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
    Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
    Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
    Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
    Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
    Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.
    Zomer E; Owen A; Magliano DJ; Ademi Z; Reid CM; Liew D
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):121-8. PubMed ID: 23532687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The concept of the polypill in the prevention of cardiovascular disease.
    Wiley B; Fuster V
    Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cardiovascular polypill in high-risk patients.
    Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
    Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
    Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
    Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
    Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
    Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation.
    Sepanlou SG; Farzadfar F; Jafari E; Danaei G
    Arch Iran Med; 2012 Sep; 15(9):531-7. PubMed ID: 22924369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
    Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
    Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The polypill to prevent cardiovascular disease: physicians' perspectives.
    Viera AJ
    Curr Opin Cardiol; 2011 Sep; 26(5):438-42. PubMed ID: 21730826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Polypill-aspostatinoprilololazide folate"--coprescription for at the risk Asian Indian in chronic non communicable diseases.
    Joshi SR
    J Assoc Physicians India; 2005 Mar; 53():175-8. PubMed ID: 15926597
    [No Abstract]   [Full Text] [Related]  

  • 16. [The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].
    Ruiz J; Egli M
    Rev Med Suisse; 2006 May; 2(68):1480-2, 1484-5. PubMed ID: 16783994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving cardiovascular protection: focus on a cardiovascular polypill.
    Barrios V; Escobar C
    Future Cardiol; 2016 Mar; 12(2):181-96. PubMed ID: 26652213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration.
    Webster R; Patel A; Billot L; Cass A; Burch C; Neal B; Usherwood T; Thom S; Poulter N; Stanton A; Bots ML; Grobbee DE; Prabhakaran D; Reddy KS; Field J; Bullen C; Elley CR; Selak V; Rafter N; Wadham A; Berwanger O; Rodgers A;
    Int J Cardiol; 2013 Dec; 170(1):30-5. PubMed ID: 24144927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.
    Lafeber M; Grobbee DE; Spiering W; van der Graaf Y; Bots ML; Visseren FL;
    Eur J Prev Cardiol; 2013 Oct; 20(5):771-8. PubMed ID: 22649123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The polypill: optimal strategy for reduction of cardiovascular disease].
    Nathoe HM; Doevendans PA
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1740. PubMed ID: 16114290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.